Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair
A021502 is closed to accrual, effective January 17, 2023, at 4:30 PM ET.
